Abstract
Purpose
The regulatory T cells (Tregs) are a subpopulation of lymphocytes that suppress the immune responses. The prognostic value of Tregs in lymphoma patients remains controversial. Thus, we conducted this meta-analysis to clarify the role of Tregs in the prognosis of lymphoma patients.
Methods
We searched PubMed, Embase, and Web of Science to obtain eligible studies that evaluated the prognostic factor of Tregs for lymphoma patients. Hazards ratios (HRs) with the matching 95% confidence intervals (95%CIs) were merged to estimate the prognostic value of Tregs.
Results
We finally retrieved 23 eligible studies, including a total of 2269 patients. The overall pooled analysis on all types of lymphomas showed that Tregs had a significantly positive association with prolonged overall survival (OS) (HR = 0.633, 95% CI 0.528–0.758) and progression-free survival (PFS) (HR = 0.451, 95% CI 0.261–0.779). Subgroup analysis indicated that high Tregs were significantly correlated with longer OS in Hodgkin lymphoma, diffuse large B cell lymphoma, and natural killer/T cell lymphoma. However, there was no significant association of Tregs with T cell lymphoma and follicular lymphoma.
Conclusions
Increased Tregs indicates a better prognosis for patients with lymphoma. Tregs could be used as a valuable prognostic biomarker of lymphoma patients.
Similar content being viewed by others
Availability of data and materials
The datasets used in this study are available from the corresponding author upon reasonable request.
Abbreviations
- Tregs:
-
Regulatory T cells
- HR:
-
Hazards ratio
- CI:
-
Confidence interval
- OS:
-
Overall survival
- PFS:
-
Progression-free survival
- NHL:
-
Non-Hodgkin lymphoma
- HL:
-
Hodgkin lymphoma
- MDSCs:
-
Myeloid-derived suppressor cells
- FOXP3:
-
Forkhead box P3
- NOS:
-
Newcastle–Ottawa Quality Assessment Scale
- BCL:
-
B-cell lymphoma
- NKTCL:
-
Natural killer/T cell lymphoma
- TCL:
-
T cell lymphoma
- FL:
-
Follicular lymphoma
- DLBCL:
-
Diffuse large B cell lymphoma
- IPI:
-
International prognostic index
- Th cells:
-
T helper cells
- CTLs:
-
Cytotoxic T cells
- DCs:
-
Dendritic cells
- T cons:
-
Conventional T cells
- cAMP:
-
Cyclic adenosine monophosphate
- IL-10:
-
Interleukin-10
- NK cells:
-
Natural killer cells
- RS cells:
-
Reed-Sternberg cells
- Tfh:
-
T follicular helper cells
- IL-2:
-
Interleukin-2
References
Ai L, Mu S, Wang Y, Wang H, Cai L, Li W, Hu Y (2018) Prognostic role of myeloid-derived suppressor cells in cancers: a systematic review and meta-analysis. BMC Cancer 18:1220. https://doi.org/10.1186/s12885-018-5086-y
Ai L et al (2019) Myeloid-derived suppressor cells endow stem-like qualities to multiple myeloma cells by inducing piRNA-823 expression and DNMT3B activation. Mol Cancer 18:88. https://doi.org/10.1186/s12943-019-1011-5
Bates GJ, Fox SB, Han C, Leek RD, Garcia JF, Harris AL, Banham AH (2006) Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 24:5373–5380. https://doi.org/10.1200/jco.2006.05.9584
Blaker YN et al (2016) The tumour microenvironment influences survival and time to transformation in follicular lymphoma in the rituximab era. Br J Haematol 175:102–114. https://doi.org/10.1111/bjh.14201
Bonzheim I et al (2008) Evaluation of FoxP3 expression in peripheral T cell lymphoma. Am J Clin Pathol 130:613–619. https://doi.org/10.1309/l65gweq803pp6vx1
Borsellino G et al (2007) Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 110:1225–1232. https://doi.org/10.1182/blood-2006-12-064527
Cao X, Cai SF, Fehniger TA, Song J, Collins LI, Piwnica-Worms DR, Ley TJ (2007) Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity 27:635–646. https://doi.org/10.1016/j.immuni.2007.08.014
Carreras J et al (2006) High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood 108:2957–2964. https://doi.org/10.1182/blood-2006-04-018218
Carreras J et al (2019) High TNFRSF14 and low BTLA are associated with poor prognosis in follicular lymphoma and in diffuse large B cell lymphoma transformation. J Clin Exp Hematopathol 59:1–16. https://doi.org/10.3960/jslrt.19003
Chao C et al (2015) Stromal immune infiltration in HIV-related diffuse large B cell lymphoma is associated with HIV disease history and patient survival. Aids 29:1943–1951. https://doi.org/10.1097/qad.0000000000000780
Chetaille B et al (2009) Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome. Blood 113:2765–3775. https://doi.org/10.1182/blood-2008-07-168096
Curiel TJ et al (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10:942–949. https://doi.org/10.1038/nm1093
Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634. https://doi.org/10.1136/bmj.315.7109.629
El-Dien MMS, Abdou AG, Asaad NY, Abd El-Wahed MM, Kora MAE-HM (2017) Intratumoral FOXP3+regulatory T cells in diffuse large B cell lymphoma. Appl Immunohistochem Mol Morphol 25:534–542
Finn OJ (2012) Immuno–oncology: understanding the function and dysfunction of the immune system in cancer. Ann Oncol 23(Suppl 8):viii6–9. https://doi.org/10.1093/annonc/mds256
Gabrilovich DI (2017) Myeloid-derived suppressor cells. Cancer Immunol Res 5:3–8. https://doi.org/10.1158/2326-6066.Cir-16-0297
Giallongo C et al (2016) Granulocyte-like myeloid derived suppressor cells (G-MDSC) are increased in multiple myeloma and are driven by dysfunctional mesenchymal stem cells (MSC). Oncotarget 7:85764–85775. https://doi.org/10.18632/oncotarget.7969
Gjerdrum LM et al (2007) FOXP3+ regulatory T cells in cutaneous T cell lymphomas: association with disease stage and survival. Leukemia 21:2512–2518. https://doi.org/10.1038/sj.leu.2404913
Gomez-Gelvez JC, Salama ME, Perkins SL, Leavitt M, Inamdar KV (2016) Prognostic impact of tumor microenvironment in diffuse large B cell lymphoma uniformly treated with R-CHOP chemotherapy. Am J Clin Pathol 145:514–523. https://doi.org/10.1093/ajcp/aqw034
Görgün GT et al (2013) Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans. Blood 121:2975–2987. https://doi.org/10.1182/blood-2012-08-448548
Greaves P et al (2013) Expression of FOXP3, CD68, and CD20 at diagnosis in the microenvironment of classical Hodgkin lymphoma is predictive of outcome. J Clin Oncol 31:256–262. https://doi.org/10.1200/JCO.2011.39.9881
Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560. https://doi.org/10.1136/bmj.327.7414.557
Hori S, Nomura T, Sakaguchi S (2003) Control of regulatory T cell development by the transcription factor Foxp3. Science 299:1057–1061. https://doi.org/10.1126/science.1079490
Kelley TW, Pohlman B, Elson P, Hsi ED (2007) The ratio of FOXP3+ regulatory T cells to granzyme B+ cytotoxic T/NK cells predicts prognosis in classical Hodgkin lymphoma and is independent of bcl-2 and MAL expression. Am J Clin Pathol 128:958–965. https://doi.org/10.1309/nb3947k383dj0lq2
Khan G (2006) Epstein-Barr virus, cytokines, and inflammation: a cocktail for the pathogenesis of Hodgkin's lymphoma? Exp Hematol 34:399–406. https://doi.org/10.1016/j.exphem.2005.11.008
Kim WY et al (2009) Increased quantity of tumor-infiltrating FOXP3-positive regulatory T cells is an independent predictor for improved clinical outcome in extranodal NK/T cell lymphoma. Ann Oncol 20:1688–1696. https://doi.org/10.1093/annonc/mdp056
Lam ST et al (2020) A new immunological prognostic model based on immunohistochemistry for extranodal natural killer/T cell lymphoma patients after non-anthracycline-based chemotherapy. Cancer Manag Res 12:1981–1990. https://doi.org/10.2147/CMAR.S244176
Lee N-R et al (2008) Prognostic impact of tumor infiltrating FOXP3 positive regulatory T cells in diffuse large B cell lymphoma at diagnosis. Leukemia Lymphoma 49:247–256. https://doi.org/10.1080/10428190701824536
Li X, Lu P, Li B, Zhang W, Yang R, Chu Y, Luo K (2017) Interleukin 2 and interleukin 10 function synergistically to promote CD8(+) T cell cytotoxicity, which is suppressed by regulatory T cells in breast cancer. Int J Biochem Cell Biol 87:1–7. https://doi.org/10.1016/j.biocel.2017.03.003
Lindqvist CA et al (2011) Both CD4+ FoxP3+ and CD4+ FoxP3- T cells from patients with B-cell malignancy express cytolytic markers and kill autologous leukaemic B cells in vitro. Immunology 133:296–306. https://doi.org/10.1111/j.1365-2567.2011.03439.x
Lundberg J, Berglund D, Molin D, Kinch A (2019) Intratumoral expression of FoxP3-positive regulatory T cells in T cell lymphoma: no correlation with survival Upsala. J Med Sci 124:105–110
Lv M, Wang K, Huang XJ (2019) Myeloid-derived suppressor cells in hematological malignancies: friends or foes. J Hematol Oncol 12:105. https://doi.org/10.1186/s13045-019-0797-3
Marinova E, Han S, Zheng B (2007) Germinal center helper T cells are dual functional regulatory cells with suppressive activity to conventional CD4+ T cells. J Immunol 178:5010–5017. https://doi.org/10.4049/jimmunol.178.8.5010
Matasar MJ, Zelenetz AD (2008) Overview of lymphoma diagnosis and management. Radiol Clin North Am 46(175–198):vii. https://doi.org/10.1016/j.rcl.2008.03.005
Muenst S, Hoeller S, Dirnhofer S, Tzankov A (2009) Increased programmed death-1+ tumor-infiltrating lymphocytes in classical Hodgkin lymphoma substantiate reduced overall survival. Hum Pathol 40:1715–1722. https://doi.org/10.1016/j.humpath.2009.03.025
Najafi M, Farhood B, Mortezaee K (2019) Contribution of regulatory T cells to cancer: a review. J Cell Physiol 234:7983–7993. https://doi.org/10.1002/jcp.27553
Nakayama S et al (2017) Infiltration of effector regulatory T cells predicts poor prognosis of diffuse large B cell lymphoma, not otherwise specified. Blood Adv 1:486–493. https://doi.org/10.1182/bloodadvances.2016000885
Nam SJ, Go H, Paik JH, Kim TM, Heo DS, Kim CW, Jeon YK (2014) An increase of M2 macrophages predicts poor prognosis in patients with diffuse large B cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone. Leuk Lymphoma 55:2466–2476. https://doi.org/10.3109/10428194.2013.879713
Parmar MK, Torri V, Stewart L (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17:2815–2834. https://doi.org/10.1002/(sici)1097-0258(19981230)17:24<2815:aid-sim110>3.0.co;2-8
Peng RJ et al (2011) Circulating and tumor-infiltrating Foxp3(+) regulatory T cell subset in Chinese patients with extranodal NK/T cell lymphoma. Int J Biol Sci 7:1027–1036. https://doi.org/10.7150/ijbs.7.1027
Richendollar BG, Pohlman B, Elson P, Hsi ED (2011) Follicular programmed death 1-positive lymphocytes in the tumor microenvironment are an independent prognostic factor in follicular lymphoma. Hum Pathol 42:552–557. https://doi.org/10.1016/j.humpath.2010.08.015
Ring S, Karakhanova S, Johnson T, Enk AH, Mahnke K (2010) Gap junctions between regulatory T cells and dendritic cells prevent sensitization of CD8(+) T cells. J Allergy Clin Immunol 125(237–246):e231–237. https://doi.org/10.1016/j.jaci.2009.10.025
Ring S et al (2015) Regulatory T cell-derived adenosine induces dendritic cell migration through the Epac-Rap1 pathway. J Immunol 194:3735–3744. https://doi.org/10.4049/jimmunol.1401434
Roncador G et al (2005) FOXP3, a selective marker for a subset of adult T cell leukaemia/lymphoma. Leukemia 19:2247–2253. https://doi.org/10.1038/sj.leu.2403965
Rueda CM, Jackson CM, Chougnet CA (2016) Regulatory T cell-mediated suppression of conventional T cells and dendritic cells by different cAMP intracellular pathways. Front Immunol 7:216. https://doi.org/10.3389/fimmu.2016.00216
Saifi M et al (2010) High ratio of interfollicular CD8/FOXP3-positive regulatory T cells is associated with a high FLIPI index and poor overall survival in follicular lymphoma. Exp Therap Med 1:933–938
Saito E, Matsuoka J (2020) International comparison of Hodgkin and non-Hodgkin lymphoma incidence. Jpn J Clin Oncol 50:96–97. https://doi.org/10.1093/jjco/hyz202
Sauerbrei W, Taube SE, McShane LM, Cavenagh MM, Altman DG (2018) Reporting recommendations for tumor marker prognostic studies (REMARK): an abridged explanation and elaboration. J Natl Cancer Inst 110:803–811. https://doi.org/10.1093/jnci/djy088
Sawant DV et al (2019) Adaptive plasticity of IL-10(+) and IL-35(+) T(reg) cells cooperatively promotes tumor T cell exhaustion. Nat Immunol 20:724–735. https://doi.org/10.1038/s41590-019-0346-9
Shang B, Liu Y, Jiang SJ, Liu Y (2015) Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis. Sci Rep 5:15179. https://doi.org/10.1038/srep15179
Shankland KR, Armitage JO, Hancock BW (2012) Non-Hodgkin lymphoma. Lancet 380:848–857. https://doi.org/10.1016/s0140-6736(12)60605-9
Siegel RL, Miller KD (2020) Cancer statistics, 2020. CA Cancer J Clin 70:7–30. https://doi.org/10.3322/caac.21590
Sun L et al (2017) Clinicopathologic and prognostic significance of regulatory T cells in patients with hepatocellular carcinoma: a meta-analysis. Oncotarget 8:39658–39672. https://doi.org/10.18632/oncotarget.17340
Tzankov A, Meier C, Hirschmann P, Went P, Pileri SA, Dirnhofer S (2008) Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma. Haematologica 93:193–200. https://doi.org/10.3324/haematol.11702
Ueno H (2016) Human circulating T follicular helper cell subsets in health and disease. J Clin Immunol 36(Suppl 1):34–39. https://doi.org/10.1007/s10875-016-0268-3
Wang C et al (2018) PD-1, FOXP3, and CSF-1R expression in patients with Hodgkin lymphoma and their prognostic value. Int J Clin Exp Pathol 11:1923–1934
Xu P, Fan W, Zhang Z, Wang J, Wang P, Li Y, Yu M (2017) The clinicopathological and prognostic implications of FoxP3(+) regulatory T cells in patients with colorectal cancer: a meta-analysis. Front Physiol 8:950. https://doi.org/10.3389/fphys.2017.00950
Zhao DM, Thornton AM, DiPaolo RJ, Shevach EM (2006) Activated CD4+CD25+ T cells selectively kill B lymphocytes. Blood 107:3925–3932. https://doi.org/10.1182/blood-2005-11-4502
Funding
This work was supported by grants of the National Natural Science Foundation of China (No 81500172 for Lisha Ai and No 81202962 for You Qin).
Author information
Authors and Affiliations
Contributions
FP and YQ collected and analyzed the data, wrote the paper. FP, YQ, SM and JL analyzed the data and wrote the paper. LA and YH conceived and designed this study, analyzed the data, wrote the paper. All authors read and approved the final manuscript.
Corresponding authors
Ethics declarations
Conflict of interest
The authors have declared that no competing interest exists.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Peng, F., Qin, Y., Mu, S. et al. Prognostic role of regulatory T cells in lymphoma: a systematic review and meta-analysis. J Cancer Res Clin Oncol 146, 3123–3135 (2020). https://doi.org/10.1007/s00432-020-03398-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-020-03398-1